



VF001002 CLINICAL TRIAL UPDATE: Strong performance in October driven by new sites

Brisbane, Australia 2nd November 2017: Factor Therapeutics Limited (ASX: FTT, the “Company”), an Australian biomedical company developing therapeutics for advanced wound care, is pleased to confirm that operations at sites in its Phase 2b VF00102 study affected by recent hurricane activity are now fully recovered; and the four newest sites have all successfully entered patients into the trial.

During October 2017, the company saw a substantial uplift in site activity, with a total of 26 new patients entered into the screening phase and eight enrolled into the trial at the completion of the two-week standard treatment period.

The two sites in Puerto Rico became fully operational in the latter part of October and have delivered the strongest start-up screening activity of any sites in the trial to date.

All other sites in the trial have returned to previous levels of activity, improving on the summer and hurricane season which affected recruitment rates in the previous quarter.

“October was the strongest month we’ve experienced to date for patients entered into screening and this is very encouraging, as this screening phase represents the pipeline of patients who will go on to be randomised. We’re especially pleased that our four new sites have been able to contribute quickly and the sites in Puerto Rico have had such a strong screening performance.” said Dr Rosalind Wilson, CEO of Factor Therapeutics.

“The progress we’ve made in October ensures we remain on track to meet our targeted timeframe to complete enrolment, and reaffirms the importance of our active management strategy, which has seen us reconfigure our sites, invest in media and advertising and work closely with our clinicians to optimise recruitment.”

-ENDS-

Corporate Contact

Dr. Rosalind Wilson
Chief Executive Officer
Factor Therapeutics Limited
r.wilson@factor-therapeutics.com

Investor Relations Contact

Kyahn Williamson
Head of Investor Communication
WE Buchan
kwilliamson@we-buchan.com

About Factor Therapeutics

Factor Therapeutics Limited (“Factor”) is a biomedical technology company that is developing treatments for acute and chronic wound healing applications. Factor is a clinical stage company with its lead program (VF-001) in Phase II for the treatment of venous leg ulcers (VLUs). The company is also developing solutions for a variety of interventional wound care and serious orphan dermatology conditions. The company’s platform technology originates from the Institute of Health and Biomedical Innovation at the Queensland University of Technology (QUT), Australia. Factor’s shares are traded on the Australian Securities Exchange (ASX) under the ticker FTT. For more information, please visit <https://factor-therapeutics.com>.